Valneva said regaining full rights to the vaccine will allow the company to “assume direct control over its supply chain and commercialization for endemic high-risk countries
Pembrolizumab has shown meaningful benefit only when combined with chemotherapy
The company said it received notice on January 1 from the FDA’s Center for Veterinary Medicine that the funding will support its ongoing effectiveness study of Canalevia-CA1
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
The approval is supported by data from three pivotal clinical trials
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
The Phase II study will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of 9MW3811 in patients with pathological scarring
Dr. Chand held several leadership positions within AstraZeneca and the broader biopharmaceutical industry
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
